Zyn Meets Adderall? TINA.org Takes Action against Ultra’s Deceptive Marketing
Why regulators need to step in and what’s at stake.
A group of consumers who purchased Nexium, a heartburn medication, in Massachusetts since March 2001 filed a class-action lawsuit against AstraZeneca. They claimed that the pharmaceutical company deceptively marketed the medication as superior to its other heartburn drugs so that consumers would buy the more expensive Nexium. In October 2012, AstraZeneca agreed to settle the lawsuit but the terms of the settlement have not yet been announced. (Commonwealth Care Alliance v. AstraZeneca Pharmaceuticals L.P., Case No. 05-0269)
Why regulators need to step in and what’s at stake.
When you find the thing you never knew you needed, it can bring everyone together.
Purported closing-down sale is deceiving consumers, with the help of AI.
Company hits snooze on promised marketing changes.
Matt Gephardt, KSL.com